Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Drug repurposing for the treatment of COVID-19

Yuri Kato a, Kazuhiro Nishiyama a, Akiyuki Nishimura b, c, d, Takamasa Noda e, f, g, h, Kaori Okabe e, Takahiro Kusakabe i, Yasunari Kanda j, Motohiro Nishida a, b, c, *

a Department of Physiology, Graduate School of Pharmaceutical Science, Kyushu University, Fukuoka, Japan
b Division of Cardiocirculatory Signaling, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Okazaki, Aichi, Japan
c Department of Creative Research, Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences, Okazaki, Aichi, Japan
d Department of Physiological Sciences, SOKENDAI, Okazaki, Aichi, Japan
e Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan
f Department of Psychiatric Research, Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences, Okazaki, Aichi, Japan
g Department of Psychiatric Research, Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences, Okazaki, Aichi, Japan
h Department of Psychology, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan
i Division of Insect Genome Science, Graduate School of Bioscience and Bioinformatics, Kyushu University, Fukuoka, Japan
j Division of Pharmacology, National Institute of Health Sciences, Kawasaki, Japan

A R T I C L E   I N F O

Article history:
Received 7 March 2022
Received in revised form 4 April 2022
Accepted 19 April 2022
Available online 25 April 2022

Keywords:
Eco-pharma
Cardiomyocyte
Transient receptor potential channel
NADPH oxidase
Protein–protein interaction

A B S T R A C T

Coronavirus disease 2019 (COVID-19) remains prevalent worldwide since its onset was confirmed in Wuhan, China in 2019. Vaccines against the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have shown a preventive effect against the onset and severity of COVID-19, and social and economic activities are gradually recovering. However, the presence of vaccine-resistant variants has been reported, and the development of therapeutic agents for patients with severe COVID-19 and related sequelae remains urgent. Drug repurposing, also called drug repositioning or eco-pharma, is the strategy of using previously approved and safe drugs for a therapeutic indication that is different from their original indication. The risk of severe COVID-19 and mortality increases with advancing age, cardiovascular disease, hypertension, diabetes, and cancer. We have reported three protein–protein interactions that are related to heart failure, and recently identified that one mechanism increases the risk of SARS-CoV-2 infection in mammalian cells. This review outlines the global efforts and outcomes of drug repurposing research for the treatment of severe COVID-19. It also discusses our recent finding of a new protein–protein interaction that is common to COVID-19 aggravation and heart failure.

© 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

In late 2019, COVID-19 rapidly became prevalent throughout the world. Since then, many related studies have been carried out, such as decoding the genome of SARS-CoV-2 and elucidating its infection patterns and disease aggravation mechanisms. Various COVID-19 sequelae such as vasculitis, pulmonary fibrosis, heart failure, and loss of smell and taste have been reported. Although SARS-CoV-2 vaccination campaigns are underway, several SARS-CoV-2 variants have emerged, and each has caused a wave of infections. Worryingly, increasing frequencies of cryptic SARS-CoV-2 lineages not found in GISAID’s EpiCoV database have been detected in New York City wastewater. These variants might enable the transfer of SARS-CoV-2 from humans to other animals. Therefore, there is an urgent need to find targets and therapeutic candidates that differ from existing therapeutic drugs.

SARS-CoV-2 invasion of human cells occurs through the following pathway. First, the SARS-CoV-2 spike protein binds to the host receptor, angiotensin-converting enzyme (ACE)2. The spike protein is then cleaved by the proteolytic enzyme TMRPSS2 and becomes activated to promote fusion between the outer viral membrane and the host cell membrane, resulting in virus internalization through endocytosis. Severe COVID-19 was initially reported to manifest as acute respiratory distress syndrome (ARDS),

https://doi.org/10.1016/j.jphs.2022.04.007
1347-8613/© 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
ACE2 is ubiquitously expressed,23,24 COVID-19 symptoms can occur of COVID-19 (Table 1). However, many patients still suffer from drugs have been approved or are in clinical trials for the treatment trials (including 2030 drug trials and 685 vaccine trials) registered breaks and disease progression. At present, there are 7605 clinical repurposing can also be cost-effective for treating disease out-

pharma,32 is an effective and rapid way to identify new uses of revealing that SARS-CoV-2 can infect heart tissue.31
diomyocytes taken from heart specimens of COVID-19 patients,
to SARS-CoV-2 infection. Viral RNA has been detected in cardiomycocytes taken from heart specimens of COVID-19 patients, revealing that SARS-CoV-2 can infect heart tissue.1

Drug repurposing, also known as drug repositioning or eco-

pharma,32 is an effective and rapid way to identify new uses of existing drugs that have a well-established safety profile. Drug repurposing can also be cost-effective for treating disease out-
breaks and disease progression. At present, there are 7605 clinical trials (including 2030 drug trials and 685 vaccine trials) registered in ClinicalTrials.gov related to COVID-19.33 Indeed, several existing drugs have been approved or are in clinical trials for the treatment of COVID-19 (Table 1). However, many patients still suffer from COVID-19 aggravation and sequelae; thus, there is a need for the rapid repurposing of drugs with mechanisms of action other than those currently approved for treating COVID-19. In this review, we discuss our efforts related to drug repurposing, focusing on the treatment of heart failure and their relation to finding new treatments for severe COVID-19.

2. Drug repurposing research for the treatment of COVID-19

Several drugs that have been previously approved to treat other diseases are being repurposed for treating COVID-19 patients; these include hydroxychloroquine, lopinavir/ritonavir, favipiravir, remdese-

vir, ivermectin, dexamethasone, camostat, and mesylate (Table 1). These drugs can be broadly classified into four groups according to their mechanism of action: inhibitors of RNA-dependent RNA polymerase; inhibitors of serine protease (TMPRSS2); inhibitors of the main cysteine protease 3CL(pro); and inhibitors of inflammation and cytokine storm (Fig. 1). Chloroquine and hydroxychloroquine have anti-parasitic ac-
tivity by increasing the lysosomal pH; these drugs have been used for over 70 years worldwide39 and also have immunosuppressive effects. Remdesivir was originally developed as a therapeutic agent for Ebola virus infection and exerts an antiviral effect by inhibiting viral RNA-dependent RNA polymerase.40 To date, four randomized controlled trials that have included a placebo have been conducted to test remdesivir. In Japan, remdesivir was approved as an anti-COVID-19 drug on May 7, 2020. Favipiravir has been approved for treating new or re-emerging influenza virus infection.41 This drug is converted to its triphosphorylated form in vivo, which selectively inhibits virus-derived RNA-dependent RNA polymerase. Camostat and nafamostat inhibit proteolytic enzymes, including TMPRSS2, and can ameliorate the acute symptoms of pancreatitis. They can also prevent coagulation of perfused blood during extracorporeal circulation in patients with hemorrhagic lesions.42,43 Lopinavir and ritonavir are protease in-
hibitors and are used as an antiretroviral medication for the treatment and prevention of HIV/AIDS.44 A fixed-dose combination of lopinavir/ ritonavir is thought to block the main cysteine protease of SARS-CoV2. Ritonavir is thought to boost the lopinavir concentration by inhibiting CYP3A4.45 The anthelmintic drug ivermectin, which is approved for the treatment of intestinal sickness and scabies, is thought to inhibit SARS-

Coronaviruses are known for their impact on the respiratory tract, but SARS-CoV-2 can also infect heart tissue,25–28 which leads to a spectrum of cardiac manifestations, including inflammation (myocarditis), arrhythmias, heart attack-like symptoms, and heart failure.48 The tropism of organs has been studied from autopsy specimens. Sequencing data revealed that SARS-CoV-2 genomic RNA was highest in the lungs, but the heart, kidney, and liver also showed substantial amounts.39 Greater than 1000 copies of SARS-

which is a severe disorder of lung function.17,18 Several factors have been identified to increase the risk for COVID-19 aggravation; these include advanced age, smoking, and pre-existing diseases such as cancer, diabetes, heart failure, and hypertension.8,19–22 Because ACE2 is ubiquitously expressed, COVID-19 symptoms can occur in organs other than the lungs. As many as 25% of SARS-CoV-2-infected patients have cardiac dysfunction,23 which is a primary symptom of COVID-19 aggravation. Because ACE2 is expressed in heart tissue, it has been suggested that SARS-CoV-2 can directly infect cardiomycocytes to impair cardiac function.26–28 In addition, the ACE2 expression level was found to be increased in the lungs of infected patients, and genome-wide analyses have shown that ACE2 expression is low in non-infected people.29,30 These findings suggest that the ACE2 expression level reflects one’s susceptibility to SARS-CoV-2 infection. Viral RNA has been detected in cardiomycocytes taken from heart specimens of COVID-19 patients, revealing that SARS-CoV-2 can infect heart tissue.1

### Table 1: Candidate approved drug for the treatment of COVID-19.

| Name                      | Mechanism of action                  | Target diseases                      |
|---------------------------|--------------------------------------|--------------------------------------|
| Hydroxychloroquine        | Increasing lysosomal pH               | Parasitic infection                  |
| Lopinavir/Ritonavir        | Inhibition of the HIV protease        | AIDS                                 |
| Favipiravir                | Inhibition of viral RNA-dependent RNA polymerase | Pandemic influenza                  |
| Remdesivir                | Inhibition of viral RNA-dependent RNA polymerase | Ebola virus disease                  |
| Ivermectin                | Activating glutamate-gated chloride channels | Parasitic infection                  |
| Dexamethasone             | Corticosteroid                        | Severe allergies etc.                |
| Camostat mesylate         | Serine protease inhibition            | Chronic pancreatitis                 |
| Baricitinib               | JAK inhibition                        | Rheumatoid arthritis                 |
| Tocilizumab               | IL-6 inhibition                       | Rheumatoid arthritis                 |
| Mavilimumab               | Human monoclonal antibody against GM-CSF | Rheumatoid arthritis                 |
| Azithromycin              | Inhibition of bacterial protein synthesis | Bacterial infection                  |
| Thalidomide               | IL-6 inhibition                       | Cancers                              |
| Methylprednisolone        | Corticosteroid                        | Inflammation                         |
| Pirfenidone               | Suppression of fibroblast proliferation and collagen production | Idiopathic pulmonary fibrosis       |
| Bromhexine hydrochloride  | Increasing of serous production in the respiratory tract and pulmonary surfactant secretion | Bronchitis                           |
| Bevacizumab               | Human monoclonal antibody against VEGF | Bronchitis                           |
| Fluvoxamine               | Inhibition of selective serotonin reuptake | Depression                           |
| Budilast                  | PDE3A, PDE4, PDE10 and PDE11 inhibition | Bronchitis                           |

HIV: human immunodeficiency virus, AIDS: acquired immunodeficiency syndrome.

JAK: Janus kinase, IL: interleukin, GM-CSF: granulocyte macrophage colony-stimulating factor.

VEGF: vascular endothelial growth factor, PDE: phosphodiesterase.
SARS-CoV-2 virus were detected in the heart of 31% of patients who died from COVID-19. In addition, a cohort study of 153,760 individuals with COVID-19 included in a national health care databases from the US Department of Veterans Affairs found that beyond the first 30 days after SARS-CoV-2 infection, individuals who has symptomatic COVID-19 were at increased risk of many types of incident cardiovascular disease, including arrhythmias, ischemic heart disease, myocarditis, and heart failure, indicating the long-term cardiovascular outcomes of COVID-19.

SARS-CoV-2 gains entry into human cells by binding to ACE2, the metallocarboxyl peptidase angiotensin receptor. ACE2 is a key enzyme that converts angiotensin (Ang) II to Ang 1-7, which in turn binds to the Mas receptor to negatively regulate Ang II-dependent signaling in the cardiovascular system. There are two isoforms of ACE2. The full-length ACE2 is located on the plasma membrane and contains the receptor binding site for the SARS-CoV-2 spike protein. The internalization of membrane ACE2 as a result of SARS-CoV-2 binding is thought to enhance Ang II-dependent signaling and to reduce Ang 1–7/Mas-mediated signaling, resulting in the increased risk of cardiovascular events. ACE2 can also occur as a soluble form that is shed into the circulation. Soluble ACE circulates at low concentrations but also contains the receptor site for the spike protein. Therefore, it is expected that an increase in soluble ACE2 relative to membrane-bound ACE2 may reduce the risk of developing cardiovascular events.

4. Drug repurposing research targeting protein–protein interactions in heart failure

We have reported three pathology-dependent protein–protein interactions (PPIs) that participate in the progression of cardiovascular remodeling in mice. The first is related to the canonical transient receptor potential (TRPC) proteins, which are thought to be molecular entities of receptor-activated cation channels. We reported that one of the diacylglycerol-activated TRPC isoforms, TRPC3, participates in oxidative stress-dependent cardiac fibrosis and left ventricular dysfunction in pressure-overloaded mouse hearts by forming a protein complex with NADPH oxidase (Nox) 2. The basal expression level of Nox2 protein is negatively regulated by the endoplasmic reticulum-associated degradation (ERAD) system. However, the interaction between TRPC3 and Nox2 prevents ERAD-dependent Nox2 degradation, leading to amplification of the Nox2-dependent production of reactive oxygen species (ROS) and ROS-mediated fibrotic signaling in cardiac cells. By screening nearly 1200 approved drugs for their ability to inhibit TRPC3–Nox2 PPI, we found that ibudilast (an anti-asthma drug) potently inhibits the formation of the TRPC3–Nox2 protein complex. Ibudilast is now in a clinical trial for the treatment of ARDS in patients hospitalized with severe COVID-19. Second, we found that G protein-coupled purinergic P2Y6 receptor (P2Y6R) mRNA expression increases with age and can interact with Ang II type 1 receptor (AT1R), which leads to the progression of Ang II-stimulated hypertension. The heterodimerization of AT1R with P2Y6R preferentially activated Ang II-stimulated Gq protein-dependent signaling, which is required for vascular smooth muscle hypertrophy. We also found that AT1R–P2Y6R heterodimerization was suppressed by treatment with the P2Y6R antagonist MRS2578, which has two isothiocyanate (ITC) residues. ITC is electrophilic, allowing it to react with the thiol residue of Cys located in the 3rd intracellular loop, leading to internalization and ubiquitylation–dependent proteasomal degradation of P2Y6R. This redox-dependent alternative internalization (REDAI) of P2Y6R is suggested to contribute to the anti-inflammatory effects of ITC-containing compounds in brightly colored vegetables, such as sulforaphane and Iberin. As several GPCRs contain the redox-sensitive Cys in the 3rd intracellular loop, the REDAI system of GPCRs is a promising new target for covalent drug development. Third, we revealed that mitochondrial hyperfusion occurs in mouse chronic heart failure after myocardial infarction through interaction between dynamin-related protein (Drp) 1 and filamin, an actin-binding protein. We also found that cilnidipine, a dihydropyridine-derivative voltage-dependent L/N-type Ca2+ channel blocker used as an anti-hypertensive drug,
potently inhibits hypoxia-induced Drp1–filamin interaction, followed by the induction of myocardial senescence after myocardial infarction. Because mitochondrial fission is also observed in other pathological organs and tissues, cilnidipine might be repurposed for the treatment of mitochondrial fission-associated intractable diseases, such as amyotrophic lateral sclerosis and muscular dystrophy. Although cilnidipine is a quite safe drug and has few side effects, its major Ca\(^{2+}\) channel blocking action will be the limitation to the repurposing of this drug for the treatment of mitochondrial fission-associated diseases. Therefore, we now synthesize cilnidipine-based derivatives to create a new compound with the same (or higher) efficacy but with lower Ca\(^{2+}\) channel blocking action.

5. ACE2 expression regulation in cardiomyocytes

Studies have verified that SARS-CoV-2 infection affects cardiac function.\(^{25–29}\) When human iPSC-derived cardiomyocytes (hiPSC-CMs) were infected with SARS-CoV-2, the spontaneous beating of hiPSC-CMs was temporarily increased but was subsequently arrested after a few days.\(^{28}\) The initial spike protein-mediated viral entry process might be the cause of the observed cardiac dysfunction. Therefore, in this review, we focus on how the ACE2 expression level is regulated in cardiomyocytes. Several diseases and lifestyle factors are reportedly risk factors for severe COVID-19; these include hypertension, diabetes, obesity, cardiac disease, older age, smoking, and anti-cancer drug treatment.\(^{8,19–22}\) We found that the myocardial ACE2 mRNA expression level increased when neonatal rat cardiac myocytes (NRCMs) were exposed to high glucose, doxorubicin (an anthracycline anticancer drug), cigarette sidestream smoke (CSS), and methylmercury. The treatment of NRCMs with ibudilast, but not cilnidipine or ITC-containing compounds, significantly suppressed the CSS-induced increase of ACE2 mRNA, suggesting the involvement of PPIs between TRPC3 and Nox2. Indeed, the increase of ACE2 protein expression in doxorubicin-treated mouse hearts was canceled by trpc3 gene deletion, and the CSS-induced increase in ACE2 mRNA expression was abolished by silencing trpc3 and nox2 genes in NRCMs. These results strongly suggest that the formation of a TRPC3–Nox2 protein complex induced by anticancer drug treatment or CSS exposure would mediate COVID-19 aggravation through ACE2 upregulation. The formation of the TRPC3–Nox2 protein complex amplifies Nox2-dependent ROS production by stabilizing the Nox2 protein. We previously reported that Nox2-dependent ROS production mediates cardiomyocyte atrophy accompanied by E3 ubiquitin ligase, atrogin-1, and muscle RING finger 1 upregulation.\(^{35,35,36}\) Thus, Nox2-dependent ROS protein may be involved in ACE2 upregulation in rodent cardiomyocytes induced by risk factors for severe COVID-19 (Fig. 3).

6. Antidepressants inhibit spike protein-induced ACE2 internalization

ACE2 receptor-dependent endocytosis is thought to be the main SARS-CoV-2 entry pathway.\(^{4,5}\) Several antidepressant drugs have
been reported to inhibit SARS-CoV viral entry by inhibiting clathrin-dependent endocytosis.\textsuperscript{61–63} We found that clomipramine, a tricycle anti-depressant drug, and trifluoperazine, a phenothiazine-derived antipsychotic drug, can inhibit TRPC3–Nox2 protein complex formation.\textsuperscript{56} Among the 12 most commonly prescribed drugs that are able to inhibit TRPC3–Nox2 complex formation, clomipramine showed the strongest inhibitory effect on ACE2 receptor internalization in HEK293T cells exposed to artificial trimeric spike protein.\textsuperscript{54,55} Clomipramine was also found to suppress the increase in SARS-CoV-2 RNA copy number in hiPS-CMs and TMPRSS2-expressing VeroE6 cells after exposure to SARS-CoV-2.\textsuperscript{63} ACE2-dependent SARS-CoV-2 viral entry is reportedly achieved through endocytosis regulated by phosphatidylinositol 3-phosphate 5-kinase (the main enzyme that synthesizes phosphatidylinositol-3,5-bisphosphate (PI(3,5)P2) in the early endosome), two-pore channel subtype 2 (a major downstream effector of PI(3,5)P2), and cathepsin L (a cysteine protease that cleaves S protein to facilitate viral entry into the lysosome). Although the molecular target of clomipramine has not yet been identified, determining the pleiotropic effects of clomipramine will promote the repurposing of this drug for the prevention and treatment of severe COVID-19. Importantly, the mechanism of action by which clomipramine inhibits SARS-CoV-2 spike protein-induced ACE2 internalization is completely different from that of remdesivir and dexamethasone, suggesting the potential for the concomitant use of clomipramine and these approved drugs for patients with severe COVID-19.

7. Future perspectives

Using knowledge of the chemicals and bioresources gained through our previous drug repurposing research, we suggest that pathology-specific PPIs (i.e., the TRPC3–Nox2 interaction) contribute to the risk of severe COVID-19 outcomes related to human heart tissue. We also believe that a pleiotropic drug that can inhibit both ACE2-dependent viral entry and ACE2 upregulation through TRPC3–Nox2 interaction would be a promising strategy for the treatment of severe COVID-19 patients with cardiac sequelae. However, there are several challenges to be overcome. Demonstrating the \textit{in vivo} efficacy of clomipramine will be required before it can be trialed in humans. Additionally, \textit{in vivo} COVID-19 studies are limited by the need for laboratories with a high biosafety level. Another problem is that because the price of repurposed drugs is low, expected profits will not be commensurate with the costs of conducting clinical trials. Clomipramine reportedly causes several adverse effects, such as cardiac arrhythimia (QT prolongation) and anti-cholinergic actions, limiting the dosage for this repurposing. However, derivatives could be synthesized based on the structure of approved drugs to create new compounds with the same (or higher) efficacy but with lower adverse effects.

More than two years have passed since the onset of the global COVID-19 pandemic. In addition to therapeutic agents, vaccines and neutralizing antibodies such as casirivimab/imdevimab, bamlanivimab/etesevimab, and sotrovimab have been developed to prevent...
SARS-CoV-2 viral entry through ACE2-dependent endocytosis. These antivirals and neutralizing antibodies are administered intravenously, but there is a demand for oral drugs that are easier to administer. The oral antivirals molnupiravir (an RNA-dependent RNA polymerase inhibitor) and nirmatrelvir (a 3CLpro inhibitor); ritonavir (a CYP3A inhibitor) combination have recently been developed and are now used to treat COVID-19.\(^7\,7^2\) Vaccination has helped to decrease the number of COVID-19 patients\(^7\,7^2\) while new SARS-CoV-2 variants (e.g., Delta and Omicron) have emerged consecutively, with the number of COVID-19 patients rapidly increasing with the rise of each new variant.\(^7\,7^2\) The wild-type virus and the known SARS-CoV-2 variants (including Omicron) require ACE2-mediated cell entry.\(^7\,7^2\) The pharmacological advantage of clomipramine lies in its potential to inhibit ACE2-mediated viral entry needed by the ancestral SARS-CoV-2 virus and its variants, as well as SARS-CoV and MERS. This advantage will promote the development of antivirals that can efficiently inhibit viral entry while reducing adverse side effects.

It is hoped that researchers will quickly identify new drugs that can be used to treat COVID-19 and deliver them to patients suffering from severe COVID-19 as soon as possible. Moreover, the number of patients suffering from COVID-19 sequelae is increasing. Various symptoms of COVID-19 sequelae have been reported, such as fatigue and depression, taste and smell disorders, and myocarditis and arrhythmia.\(^48\,77\) In the future, it will be necessary to develop animal models that mimic COVID-19 sequelae to elucidate the related underlying mechanisms and to identify new treatment strategies.

Declaration of competing interest

The authors declare no conflicts of interest.

Acknowledgments

We thank Katherine Thielges from Liwen Bianji (Edanz) (www.liwenbianji.cn) for editing the English text of a draft of this manuscript. This study was supported by Smoking Research Foundation (to M.N) and Foundation of Kinoshita Memorial Enterprise (to Y.Kato).

References

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
2. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.
3. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–452.
4. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454.
5. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e278.
6. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2020;21(3):3–20.
7. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronavirus infection on drug interactions with cardioactive medications. J Cardiovasc Drugs Ther. 2020;35(3):427–433.
8. Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438–443.
9. Lin W, Moore MJ, Vasilieva N, et al. Long COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021;13(4).
10. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):166–171.
11. Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592(7852):116–121.
12. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):137.
50. Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2.

51. Yeung ML, Teng JLL, Jia L, et al. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell. 2021;184(8):2212–2228. e2212.

52. Nishida M, Kurose H. Roles of TRP channels in the development of cardiac hypertrophy. Front Cell Infect Microbiol. 2020;10:317.

53. Kitajima N, Numaga-Tomita T, Watanabe M, et al. TRPC3 positively regulates reactive oxygen species driving maladaptive cardiac remodeling. Sci Rep. 2016;6:37001.

54. Nishiyama K, Numaga-Tomita T, Fujimoto Y, et al. Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. Br J Pharmacol. 2019;176(18):3723–3738.

55. Nishiyama K, Numaga-Tomita T, Itegin{tref}o T, et al. TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy. JCT Insight. 2017;2(15).

56. Nishiyama K, Nishimura A, Shimoda K, et al. Redox-dependent internalization of the purinergic P2Y6 receptors heterodimerize with angiotensin AT1 receptors to promote angiotensin II-induced hypertrophy. Science. 2016;9(411):ra7.

57. Nishiyama K, Nishimura A, Shimoda K, et al. Ibudilast reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 2010;107(44):19079–19083.

58. Nishiyama K, Numaga-Tomita T, Ito T, et al. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell. 2021;184(8):2212–2228. e2212.

59. Nishiyama K, Numaga-Tomita T, Fujimoto Y, et al. Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes. Br J Pharmacol. 2019;176(18):3723–3738.

60. Nishimura A, Shimoda K, Tanaka T, et al. Depolysulfated heparin with Drp1 causes mitochondrial hyperfusional cardiomyocyte atrophy. JCI Insight. 2017;2(15).

61. Lu J, Hou Y, Ge S, et al. Screened antipsychotic drugs inhibit SARS-CoV-2 virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.

62. Adamo CM, Dai DF, Percival JM, et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA. 2010;107(44):19079–19083.

63. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TDCETHER randomised, platform clinical trial. Lancet Global Health. 2022;10(1):e42–e51.

64. Fujita R, Hino M, Ebihara T, et al. Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system. Biochem Biophys Res Commun. 2020;528(2):257–262.

65. Kato Y, Yamada S, Nishiyama K, et al. Clomipramine suppresses ACE2-mediated SARS-CoV-2 entry. bioRxiv. 2021. https://doi.org/10.1101/2021.03.13.435221.

66. Kato Y, Yamada S, Nishiyama K, et al. Clomipramine suppresses ACE2-mediated SARS-CoV-2 entry. bioRxiv. 2021. https://doi.org/10.1101/2021.03.13.435221.

67. Sharun K, Tiwari R, Dhama J, Dhama K. Dexamethasone to combat cytokine storm in COVID-19: clinical trials and preliminary evidence. Int J Surg. 2020;15(716), eabj0644.

68. Liu T, Luo S, Libby P, Shi GP. Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients. Pharmacol Ther. 2020;213:107587.

69. Xu Y, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.

70. Lu J, Hou Y, Ge S, et al. Screened antipsychotic drugs inhibit SARS-CoV-2 virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.

71. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):505–520.

72. Mahase E. Covid-19: pfizer’s Paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713.

73. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dahreca G. Effect of vaccination on household transmission of SARS-CoV-2 in england. N Engl J Med. 2021;385(8):759–766.

74. Levine-Tiefenbrun M, Yelim I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790–792.

75. Buchan SA, Chung H, Brown KA, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. medRxiv. 2022. https://doi.org/10.1101/2022.12.30.21268565.

76. Cole S, Jackson L, Khan K, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv. 2021. https://doi.org/10.1101/2021.12.08.21267417.

77. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615.